Patent details
EP3743072
Title:
PHARMACEUTICAL COMPOSITION FOR SUSTAINED RELEASE DELIVERY OF BUPRENORPHINE
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
Ok
Cancel
You have not selected any documents
Ok
Unitary Effect
Unitary Effect Requested:
Yes
Unitary Effect Request Filing Date:
25/10/2023
Unitary Effect Status:
Unitary Effect Registered
Request Unitary Effect Accepted:
31/10/2023
Unitary Effect Date:
25/10/2023
Unitary Effect Registration Date:
31/10/2023
Request Unitary Effect Rejected:
Unitary Effect Re-establishment of rights Filing Date:
Unitary Effect Re-establishment of rights EPO Decision :
Unitary Effect Re-establishment of rights EPO Decision Date:
Unitary Effect Request Withdrawal Date:
Unitary Effect request has been accepted, please see the UPP register at the EPO for up-to-date information
UPP register:
EP3743072
SPC Number:
Creation Date:
Basic Information
Publication number:
EP3743072
WO Application Number:
US2019014422
Type:
European Patent Granted for NL
Status:
Unitary Effect Registered
Publication Title:
Title When Made Available For Viewing:
Reason Lapsed:
Application number:
EP19741052.5
WO Publication Number:
WO2019144079
EPO Publication Language:
English
SPC Number:
First Applicant Residence Country:
Taiwan, Chinese Taipei (TW)
Publications:
Dates
Filing date:
21/01/2019
Grant date:
25/10/2023
EP Publication Date:
02/12/2020
WO Publication Date:
25/07/2019
Claims Translations Received Date:
Claims Translation B1 Received Date:
Claims Translation B2 Received Date:
Claims Translation B3 Received Date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Published:
Due To Cession Date:
Registration date:
25/10/2023
EP B1 Publication Date:
25/10/2023
EP B2 Publication Date:
EP B3 Publication Date:
Description Translation B1 Received Date:
Description Translation B2 Received Date:
Description Translation B3 Received Date:
Expiration date:
20/01/2039
Lapsed By Expiration Date:
Revocation Date:
Invalidity Date:
Response To Novelty Search Report Received:
Patent Granting Request:
Lapsed date:
Applicant/holder
From:
25/10/2023
Name:
Foresee Pharmaceuticals Co., Ltd.
Address:
9F-2., No.19-3, Sanchong Rd
Nangang Dist., Taipei City 115, Taiwan (R.O.C.), Taiwan, Chinese Taipei (TW)
Inventor
1
Name:
LI, Yuhua
Address:
Landenberg, Pennsylvania 19350, United States of America (US)
2
Name:
LI, MingHsin
Address:
Taipei, 115, Taiwan, Chinese Taipei (TW)
3
Name:
LEE, Chen-Chang
Address:
New Taipei City, 244, Taiwan, Chinese Taipei (TW)
4
Name:
YANG, Chia-Ying
Address:
New Taipei City, 238, Taiwan, Chinese Taipei (TW)
5
Name:
LIN, Chih-Ying
Address:
Yilan City, 260, Taiwan, Chinese Taipei (TW)
Priority
Priority Patent Number:
201862620317 P
Priority Date:
22/01/2018
Priority Country:
United States of America (US)
Classification
IPC or IDT classification:
A61K 31/485 ;
A61K 9/00 ;
A61P 25/04 ;
A61P 25/36 ;
A61K 47/12 ;
A61K 47/44 ;
A61K 47/10 ;
Publication
Bulletin
1
Bulletin Heading:
UP1
Journal edition number:
48/23
Publication date:
29/11/2023
Description:
European patents with registered Unitary Effect
2
Bulletin Heading:
EP2
Journal edition number:
43/23
Publication date:
25/10/2023
Description:
European patents granted for the Netherlands
European Patent Bulletin
1
Issue number:
202348
Publication date:
29/11/2023
Description:
Unitary Effect Request Receipt
2
Issue number:
202348
Publication date:
29/11/2023
Description:
Unitary Effect Request Acceptance
3
Issue number:
202343
Publication date:
25/10/2023
Description:
Grant (B1)
Annual Fee
Annual Fee(s) Due Date:
Annual Fee Number:
Last Annual Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date
Document type
Document Description
Number of pages
File Type